DLEC1 and MLH1 Methylation in Lung Cancer
Author Information
Author(s): Seng T J, Currey N, Cooper W A, Lee C-S, Chan C, Horvath L, Sutherland R L, Kennedy C, McCaughan B, Kohonen-Corish M R J
Primary Institution: Garvan Institute of Medical Research
Hypothesis
This study investigates the association of DLEC1 and MLH1 promoter methylation with prognosis in non-small cell lung carcinoma.
Conclusion
Methylation of DLEC1 and MLH1 is associated with poor survival in non-small cell lung cancer patients.
Supporting Evidence
- DLEC1 methylation was found in 38.7% of tumors.
- MLH1 methylation was found in 35.7% of tumors.
- Concordant methylation of DLEC1 and MLH1 was the strongest independent indicator of poor prognosis.
Takeaway
This study found that changes in certain genes can help predict how well patients with lung cancer will do. If these genes are changed, it might mean the cancer is more serious.
Methodology
The study analyzed promoter methylation in 239 non-small cell lung carcinomas using methylation-specific PCR.
Limitations
The study did not assess the protein expression of DLEC1 due to the lack of available antibodies.
Participant Demographics
The cohort consisted of 155 men (64.9%) and 84 women (35.1%) with a median age of 68 years.
Statistical Information
P-Value
P=0.009
Confidence Interval
95% CI, 1.023–3.007
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website